Have any questions? 706-721-6582 or cts@augusta.edu
This prospective, observational study will help to better understand the evolving real-world treatment outcomes (including treatment patterns, reasons for discontinuation/dose reduction, treatment interruption or treatment switches), physician-reported clinical outcomes, and patient-reported symptoms and health-related quality of life (HRQoL) among patients diagnosed with mantle cell lymphoma (MCL) who newly initiated a novel therapy in the past 3 months, and treatment is ongoing at the time of enrollment.